protein tyrosine phosphatase non-receptor type 14Genealiases: CATLPH · PEZ · PTP36 · PTPD2
Q-omics provides the consensus-scored PTPN14 profile across patient tissues and cancer cell-line models. PTPN14 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTPN14 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PTPN14 RNA expression shows 19,805 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where PTPN14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN14 survival associations across molecular data types. PTPN14 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN14 RNA expression–survival associations across cancer types. High PTPN14 expression shows unfavorable associations in ACC, BLCA, LGG, PAAD and MESO, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTPN14 RNA expression.
This table summarizes PTPN14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PTPN14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN14 shows lower tumor expression in BRCA, KICH, LUAD and BLCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher PTPN14 RNA expression in tumor versus normal tissue (log2 FC = +1.098, t-test p < 0.001).
This table shows molecular features associated with PTPN14 in patient tissues and cancer cell lines. In patient samples, PTPN14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
